Seven and Eight Biopharmaceuticals Inc. Announces Acceptance of BDB001 in Combination with Pembrolizumab Interim Data to be Presented in a Poster Discussion at the 2021 ASCO Annual Meeting
  • April 28, 2021
  • Julie Ha

  EDISON, N.J. –(BUSINESS WIRE)– Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, today announced the acceptance of an abstract for a poster discussion presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.  The abstract detail […]